IASLC World Conference on Lung Cancer | Conference

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

September 18th 2024

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

September 11th 2024

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

September 11th 2024

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC

September 11th 2024

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

September 11th 2024

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial

September 11th 2024

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure

September 10th 2024

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

September 10th 2024

Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.

Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC

September 10th 2024

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC

September 10th 2024

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

September 10th 2024

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

September 10th 2024

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

September 10th 2024

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

September 9th 2024

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC

September 9th 2024

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.

Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC

September 9th 2024

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Firmonertinib Shows Antitumor Activity in EGFR PACC-Mutated NSCLC

September 9th 2024

Treatment with firmonertinib was safe and effective for patients with EGFR P-loop and αC-helix compressing-mutated non–small cell lung cancer.

Aumolertinib Improves PFS in Unresectable, Stage III EGFR+ NSCLC after Chemoradiotherapy

September 9th 2024

Treatment with aumolertinib led to an improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC

September 9th 2024

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC

September 9th 2024

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.